Systemic treatments for inflammatory breast cancer

Breast Dis. 2005-2006;22:55-65. doi: 10.3233/bd-2006-22107.

Abstract

Inflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer. The management of inflammatory breast cancer has evolved substantially over the last 40 years; current multimodality therapy regimens combine chemotherapy, surgery, and radiation. While identification of the optimal combination of these traditional therapies remains a goal, novel targeted therapies that have recently become available promise improved responses and survival. In this review, we discuss some recent developments in the use of systemic therapies for inflammatory breast cancer.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / mortality*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Biological Products / therapeutic use
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Female
  • Humans
  • Mastectomy, Modified Radical / methods
  • Middle Aged
  • Prognosis
  • Radiotherapy, Adjuvant
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biological Products